296 related articles for article (PubMed ID: 34628591)
1. Neoadjuvant therapy for pancreatic cancer.
Gugenheim J; Crovetto A; Petrucciani N
Updates Surg; 2022 Feb; 74(1):35-42. PubMed ID: 34628591
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang SQ; Zou RQ; Dai YS; Li FY; Hu HJ
Updates Surg; 2024 Jan; 76(1):1-15. PubMed ID: 37639177
[TBL] [Abstract][Full Text] [Related]
3. Perioperative and long-term survival outcomes of pancreatectomy with arterial resection in borderline resectable or locally advanced pancreatic cancer following neoadjuvant therapy: a systematic review and meta-analysis.
Xue K; Huang X; Zhao P; Zhang Y; Tian B
Int J Surg; 2023 Dec; 109(12):4309-4321. PubMed ID: 38259002
[TBL] [Abstract][Full Text] [Related]
4. Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review.
Endo Y; Kitago M; Kitagawa Y
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730584
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS.
Aoki T; Mori S; Kubota K
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473272
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers.
Miyahara S; Takahashi H; Akita H; Sasaki K; Mukai Y; Iwagami Y; Hasegawa S; Yamada D; Tomimaru Y; Noda T; Wada H; Kobayashi S; Doki Y; Eguchi H
Ann Surg Oncol; 2024 May; 31(5):2932-2942. PubMed ID: 38368291
[TBL] [Abstract][Full Text] [Related]
7. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study.
Yamada S; Hashimoto D; Yamamoto T; Yamaki S; Oshima K; Murotani K; Sekimoto M; Nakao A; Satoi S
Pancreatology; 2024 Mar; ():. PubMed ID: 38548551
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review.
Zhang C; Lizalek JM; Dougherty C; Westmark DM; Klute KA; Reames BN
Ann Surg Oncol; 2024 Feb; 31(2):792-803. PubMed ID: 37952021
[TBL] [Abstract][Full Text] [Related]
9. Therapy of Locally Advanced and Oligometastatic Pancreatic Adenocarcinoma.
Wahler IL; Damanakis A; Große Hokamp N; Bruns C; Schmidt T
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136425
[TBL] [Abstract][Full Text] [Related]
10. Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer.
Safyan RA; Kim E; Dekker E; Homs M; Aguirre AJ; Koerkamp BG; Chiorean EG
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438598. PubMed ID: 38781541
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma.
Trestini I; Cintoni M; Rinninella E; Grassi F; Paiella S; Salvia R; Bria E; Pozzo C; Alfieri S; Gasbarrini A; Tortora G; Milella M; Mele MC
World J Gastrointest Surg; 2021 Sep; 13(9):885-903. PubMed ID: 34621468
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument.
Jayakrishnan TT; Nadeem H; Groeschl RT; George B; Thomas JP; Ritch PS; Christians KK; Tsai S; Evans DB; Pappas SG; Gamblin TC; Turaga KK
HPB (Oxford); 2015 Feb; 17(2):131-9. PubMed ID: 25123702
[TBL] [Abstract][Full Text] [Related]
13. Multimodal Treatment of Resectable Esophageal Cancer.
Waters J; Sewell M; Molena D
Ann Thorac Surg; 2024 May; ():. PubMed ID: 38777248
[TBL] [Abstract][Full Text] [Related]
14. The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer.
Lang CCJ; Lloyd M; Alyacoubi S; Rahman S; Pickering O; Underwood T; Breininger SP
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267476
[TBL] [Abstract][Full Text] [Related]
15. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.
Spadi R; Brusa F; Ponzetti A; Chiappino I; Birocco N; Ciuffreda L; Satolli MA
World J Clin Oncol; 2016 Feb; 7(1):27-43. PubMed ID: 26862489
[TBL] [Abstract][Full Text] [Related]
16. Current status and future perspectives on neoadjuvant therapy in gastric cancer.
Ao S; Wang Y; Song Q; Ye Y; Lyu G
Chin J Cancer Res; 2021 Apr; 33(2):181-192. PubMed ID: 34158738
[TBL] [Abstract][Full Text] [Related]
17. Conversion of locally advanced to resectable pancreatic body cancer aided by phosphorus-32 brachytherapy (OncoSil).
Welsh F; Goodwin B; Lanka L; Allen B; Wong J; Weilert F
N Z Med J; 2023 Feb; 136(1570):78-80. PubMed ID: 36796322
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation.
Su YY; Chiang NJ; Chiu TJ; Huang CJ; Hsu SJ; Lin HC; Yang SH; Yang Y; Chou WC; Chen YY; Bai LY; Li CP; Chen JS
Biomed J; 2023 Dec; ():100696. PubMed ID: 38169173
[TBL] [Abstract][Full Text] [Related]
19. The neoadjuvant approach in resectable pancreatic ductal adenocarcinoma: lessons learned.
Henault D; Westphalen CB; O'Kane GM
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):186-188. PubMed ID: 38237623
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
